NCT01416844

Study of Immune Responses in Patients With Metastatic Melanoma

Phase II Exploratory Study of Immune Responses in Patients With Metastatic Melanoma Treated With Mouse Monoclonal Anti-OX40

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Providence Health & Services · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study, anti-OX40 will be given to patients with melanoma to find out how the immune system responds to treatment with anti-OX40. It is hoped that this treatment will cause an immune response against melanoma resulting in tumor regression, but this is not known at this time. Anti-OX40 is a large protein that can help immune cells that fight bacteria, viruses and cancer cells.

Conditions

• Metastatic Melanoma

Interventions

Type	Name	Description
BIOLOGICAL	anti-OX40	Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.

Timeline

• Start date: 2012-09-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2011-08-15
• Last updated: 2013-03-07

Locations

1 site across 1 country: United States